BMS-184476

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameBMS-184476
Drug Alias NameBMS-184476
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin inhibitors
TargetsTubulin
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSan Antonio Cancer InstituteBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A